Compare Dropbox Inc (DBX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Neurocrine Biosciences Inc — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.19B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is far larger — about 2× Dropbox Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DBX | NBIX | |
|---|---|---|
Market Cap | $7.19B | $14.60B |
Volume | 2,804,312 | 1,075,694 |
Sector | Technology | Health |
52-Week High | $37.74 | $185.50 |
52-Week Low | $22.06 | $123.10 |
Typical Hold Time | 97 Days | 23 Days |
Enterprise Value | $10.05B | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $34.14, up 1.22% on the day, with a bearish technical signal and mixed analyst ratings. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $0.728. Revenue remains stable around $2.5B annually, with a high gross margin of 79.72%, but net cash flow turned negative in 2025 due to significant financing outflows. Recent news highlights insider selling and a security breach affecting 5,000 accounts.
The outlook is cautious; while profitability is solid, stagnant revenue growth and high debt levels pose risks. The consensus price target of $26.83 suggests downside potential. Investor sentiment is divided, with technical indicators signaling bearish pressure. Key risks include competitive threats and execution challenges in a mature market.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
